Advanced search
1 file | 1.29 MB Add to list

Should we target TNF receptors in the intestinal epithelium with glucocorticoids during systemic inflammation?

Kelly Van Looveren (UGent) and Claude Libert (UGent)
Author
Organization
Abstract
Introduction: Reverting Systemic inflammatory response syndromes (SIRS), particularly sepsis, is a huge challenge of contemporary medicine. Inhibition of the cytokine tumor necrosis factor alpha (TNF alpha), originally considered as a mediator in sepsis, has led to frustrating results. Equally so, glucocorticoids (GCs), renowned for their role in numerous inflammatory diseases, remain controversial in sepsis. Areas covered: We discuss how, in SIRS, the intestinal epithelium is a critical TNF-responsive target. Inhibition of TNF receptor 1 (TNFR1), rather than TNF, may be a more targeted and safe therapeutic approach. In intestinal epithelial cells (IECs), a strong interplay between GCs and TNF exists. Addressing GCs in these cells is crucial in SIRS and sepsis and would avoid dose-limiting off-target effects, for example on immune cells and phagocytes. Expert opinion: The targeting of TNFR1 specifically at the level of IECs, potentially combined with IEC-specific stimulation of GR, could lead to a more safe and targeted treatment for SIRS and sepsis.
Keywords
TUMOR-NECROSIS-FACTOR, PSEUDOMONAS-AERUGINOSA PNEUMONIA, MULTIPLE ORGAN, DYSFUNCTION, SAFE ANTITUMOR THERAPY, SPECIAL-ISSUE SEPSIS, BARRIER, DYSFUNCTION, CRITICAL ILLNESS, BOWEL-DISEASE, IMPROVES SURVIVAL, LETHAL-SHOCK, Glucocorticoids, inflammation, intestinal epithelium, TNF, TNFR1, sepsis, SIRS, Reverting Systemic inflammatory response syndromes

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 1.29 MB

Citation

Please use this url to cite or link to this publication:

MLA
Van Looveren, Kelly, and Claude Libert. “Should We Target TNF Receptors in the Intestinal Epithelium with Glucocorticoids During Systemic Inflammation?” EXPERT OPINION ON THERAPEUTIC TARGETS 22.12 (2018): 1029–1037. Print.
APA
Van Looveren, K., & Libert, C. (2018). Should we target TNF receptors in the intestinal epithelium with glucocorticoids during systemic inflammation? EXPERT OPINION ON THERAPEUTIC TARGETS, 22(12), 1029–1037.
Chicago author-date
Van Looveren, Kelly, and Claude Libert. 2018. “Should We Target TNF Receptors in the Intestinal Epithelium with Glucocorticoids During Systemic Inflammation?” Expert Opinion on Therapeutic Targets 22 (12): 1029–1037.
Chicago author-date (all authors)
Van Looveren, Kelly, and Claude Libert. 2018. “Should We Target TNF Receptors in the Intestinal Epithelium with Glucocorticoids During Systemic Inflammation?” Expert Opinion on Therapeutic Targets 22 (12): 1029–1037.
Vancouver
1.
Van Looveren K, Libert C. Should we target TNF receptors in the intestinal epithelium with glucocorticoids during systemic inflammation? EXPERT OPINION ON THERAPEUTIC TARGETS. 2018;22(12):1029–37.
IEEE
[1]
K. Van Looveren and C. Libert, “Should we target TNF receptors in the intestinal epithelium with glucocorticoids during systemic inflammation?,” EXPERT OPINION ON THERAPEUTIC TARGETS, vol. 22, no. 12, pp. 1029–1037, 2018.
@article{8600884,
  abstract     = {Introduction: Reverting Systemic inflammatory response syndromes (SIRS), particularly sepsis, is a huge challenge of contemporary medicine. Inhibition of the cytokine tumor necrosis factor alpha (TNF alpha), originally considered as a mediator in sepsis, has led to frustrating results. Equally so, glucocorticoids (GCs), renowned for their role in numerous inflammatory diseases, remain controversial in sepsis.
Areas covered: We discuss how, in SIRS, the intestinal epithelium is a critical TNF-responsive target. Inhibition of TNF receptor 1 (TNFR1), rather than TNF, may be a more targeted and safe therapeutic approach. In intestinal epithelial cells (IECs), a strong interplay between GCs and TNF exists. Addressing GCs in these cells is crucial in SIRS and sepsis and would avoid dose-limiting off-target effects, for example on immune cells and phagocytes.
Expert opinion: The targeting of TNFR1 specifically at the level of IECs, potentially combined with IEC-specific stimulation of GR, could lead to a more safe and targeted treatment for SIRS and sepsis.},
  author       = {Van Looveren, Kelly and Libert, Claude},
  issn         = {1472-8222},
  journal      = {EXPERT OPINION ON THERAPEUTIC TARGETS},
  keywords     = {TUMOR-NECROSIS-FACTOR,PSEUDOMONAS-AERUGINOSA PNEUMONIA,MULTIPLE ORGAN,DYSFUNCTION,SAFE ANTITUMOR THERAPY,SPECIAL-ISSUE SEPSIS,BARRIER,DYSFUNCTION,CRITICAL ILLNESS,BOWEL-DISEASE,IMPROVES SURVIVAL,LETHAL-SHOCK,Glucocorticoids,inflammation,intestinal epithelium,TNF,TNFR1,sepsis,SIRS,Reverting Systemic inflammatory response syndromes},
  language     = {eng},
  number       = {12},
  pages        = {1029--1037},
  title        = {Should we target TNF receptors in the intestinal epithelium with glucocorticoids during systemic inflammation?},
  url          = {http://dx.doi.org/10.1080/14728222.2018.1539078},
  volume       = {22},
  year         = {2018},
}

Altmetric
View in Altmetric
Web of Science
Times cited: